According to Halozyme Therapeutics's latest financial reports the company's current EPS (TTM) is 1,68 โฌ. In 2022 the company made an earnings per share (EPS) of 1,43 โฌ a decrease over its 2021 EPS that were of 2,75 โฌ.
Year | EPS | Change |
---|---|---|
2023 (TTM) | 1,65 โฌ | 15.42% |
2022 | 1,43 โฌ | -48.07% |
2021 | 2,75 โฌ | 196.88% |
2020 | 0,93 โฌ | -292% |
2019 | -0,48 โฌ | -9.09% |
2018 | -0,53 โฌ | -237.5% |
2017 | 0,39 โฌ | -149.38% |
2016 | -0,78 โฌ | 211.54% |
2015 | -0,25 โฌ | -52.73% |
2014 | -0,53 โฌ | -24.66% |
2013 | -0,70 โฌ | 48.98% |
2012 | -0,47 โฌ | 145% |
2011 | -0,19 โฌ | -64.29% |
2010 | -0,54 โฌ | -17.65% |
2009 | -0,66 โฌ | 9.68% |
2008 | -0,60 โฌ | 93.75% |
2007 | -0,31 โฌ | 33.33% |
2006 | -0,23 โฌ | -4% |
2005 | -0,24 โฌ | -3.85% |
2004 | -0,25 โฌ | -13.33% |
2003 | -0,29 โฌ | 83.59% |
2002 | -0,16 โฌ |